Table 1.
Condition | Prevalence |
Recommended work-up | |
---|---|---|---|
BCS | PVT | ||
Myeloproliferative neoplasm | 30–57% | 21–25% | Systematic genetic testing of the V617F mutation of the JAK2 gene in all patients. If negative:
|
JAK2 V617F | 28–45% | 15–21% | |
CALR mutation | 1–3% | 1–2% | |
Inherited thrombophilic disorders | Genetic testing for prothrombin G202101A and Factor V Leiden mutationsProtein S activity Protein C activity Antithrombin activity Protein S, C and antithrombin activities should be assessed in the absence of VKAs. Cautious interpretation of impaired liver function |
||
G20210A prothrombin gene mutation | 12% | 5% | |
Factor V Leiden mutation | 4% | 8% | |
Antithrombin deficiency | 3% | 5% | |
Protein C deficiency | 2% | 1% | |
Protein S deficiency | 2% | 2% | |
Acquired thrombophilic disorders | |||
Antiphospholipid antibody syndrome | 5% | 5% | Lupus anticoagulant, anti-cardiolipin, and anti-beta2 glycoprotein 1 antibody testing Repeat testing after 12 weeks in case of positive testing |
Paroxysmal nocturnal hemoglobinuria | 10% | 0-0.5% | Flow cytometry analysis |
Behcet’s disease | 1-2% | Uncommon | No specific testing, clinical diagnosis Suspect Behcet's disease if: male sex, Mediterranean origin IVC stenosis, genital/oral ulcers, deep vein thrombosis in other sites, arterial thrombosis |
Coeliac disease | 1.4% | 0.7% | Anti-transglutaminase antibody +/- duodenal biopsies |
Other systemic factors
|
Search clinical and/or laboratory features CMV IgM and CMV PCR (blood) |
||
Hormonal factors
|
∼30% | ∼20% | Clinical context Search for introduction/modification of oral contraception within 6 months before diagnosis |
Local factors
|
0-3% | 20 % | CT scan Colonoscopy |
No identified factor | 10-29% | 15-40% |
BCS, Budd-Chiari syndrome; CMV, cytomegalovirus; IVC, inferior vena cava; PVT, portal vein thrombosis; VKAs, vitamin K antagonists.